Patents by Inventor Gunnar J. Hanson

Gunnar J. Hanson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHIMERIC PEPTIDES FOR ANTISENSE DELIVER
    Publication number: 20210260206
    Abstract: Provided herein are oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, chimeric peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: March 15, 2019
    Publication date: August 26, 2021
    Applicants: Sarepta Therapeutics, Inc., Massachusetts Institute of Technology
    Inventors: Bradley L. PENTELUTE, Colin M. FADZEN, Rebecca L. HOLDEN, Justin M. WOLFE, Zi-Ning CHOO, Monica YAO, Gunnar J. HANSON
  • Peptide oligonucleotide conjugates
    Patent number: 11097011
    Abstract: Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: August 24, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Ming Zhou
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20210169919
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Application
    Filed: November 19, 2020
    Publication date: June 10, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY
    Publication number: 20210169918
    Abstract: The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.
    Type: Application
    Filed: November 23, 2020
    Publication date: June 10, 2021
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Methods and compounds for treatment of lymphocyte-related diseases and conditions
    Patent number: 11020417
    Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: June 1, 2021
    Assignee: Sarepta Therapeutics, Inc
    Inventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak
  • Peptide Oligonucleotide Conjugates
    Publication number: 20210139896
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: May 7, 2020
    Publication date: May 13, 2021
    Inventor: Gunnar J. Hanson
  • OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
    Publication number: 20210139897
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: July 23, 2020
    Publication date: May 13, 2021
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20210138079
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Application
    Filed: July 24, 2020
    Publication date: May 13, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. HANSON, Marco A. Passini, Frederick Joseph Schnell
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 11000600
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: May 11, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY
    Publication number: 20210077628
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 18, 2021
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • Compound and method for treating myotonic dystrophy
    Patent number: 10927378
    Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: February 23, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Ryszard Kole, Gunnar J. Hanson
  • Modified antisense oligomers for exon inclusion in spinal muscular atrophy
    Patent number: 10905709
    Abstract: The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: February 2, 2021
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 10888578
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20200377886
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: June 1, 2018
    Publication date: December 3, 2020
    Applicant: SAREPTA THERAPEUTICS, INC.
    Inventors: Marco A. PASSINI, Gunnar J. HANSON
  • PROCESSES FOR PREPARING PHOSPHORODIAMIDATE MORPHOLINO OLIGOMERS VIA FAST-FLOW SYNTHESIS
    Publication number: 20200362339
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Application
    Filed: September 25, 2018
    Publication date: November 19, 2020
    Inventors: Kyle A. Totaro, Mark D. Simon, Ming Zhou, Hong Zong, Gunnar J. Hanson, Bradley L. Pentelute
  • Cell-Penetrating Peptides For Antisense Delivery
    Publication number: 20200316210
    Abstract: Provided herein are oligonucleotides, cell penetrating peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: October 17, 2018
    Publication date: October 8, 2020
    Inventors: Justin M. Wolfe, Colin M. Fadzen, Zi-Ning Choo, Rebecca L. Holden, Monica Yao, Gunnar J. Hanson, Bradley L. Pentelute
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 10765760
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 8, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Gunnar J. Hanson, Marco A. Passini, Frederick Joseph Schnell
  • Peptide Oligonucleotide Conjugates
    Publication number: 20200277598
    Abstract: Oligonucleotide analogues conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Application
    Filed: October 4, 2019
    Publication date: September 3, 2020
    Inventor: Gunnar J. Hanson
  • Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
    Patent number: 10760078
    Abstract: Oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3? and/or 5?-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 1, 2020
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventors: Gunnar J. Hanson, Alexander Charles Rudolph, Bao Zhong Cai, Ming Zhou, Dwight D. Weller
  • Peptide Oligonucleotide Conjugates
    Publication number: 20200254109
    Abstract: Provided herein are oligonucleotides, peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease, a viral infection, or a bacterial infection in a subject in need thereof, comprising administering to the subject oligonucleotides, peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 13, 2020
    Inventors: Gunnar J. Hanson, Ming Zhou